Govindan, R., Fakih, M., Price, T., Falchook, G., Desai, J., Kuo, J., … Hong, D. (2019). OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC. In Journal of Thoracic Oncology (Vol. 14, pp. S208–S208). Elsevier BV. https://doi.org/10.1016/j.jtho.2019.08.412

Govindan, R., M. Fakih, T. Price, G. Falchook, J. Desai, J. Kuo, J. Strickler, et al. “OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC.” In Journal of Thoracic Oncology, 14:S208–S208. Elsevier BV, 2019. https://doi.org/10.1016/j.jtho.2019.08.412.

Govindan R, Fakih M, Price T, Falchook G, Desai J, Kuo J, et al. OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC. In: Journal of Thoracic Oncology. Elsevier BV; 2019. p. S208–S208.

Govindan, R., et al. “OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC.” Journal of Thoracic Oncology, vol. 14, no. 10, Elsevier BV, 2019, pp. S208–S208. Crossref, doi:10.1016/j.jtho.2019.08.412.

Govindan R, Fakih M, Price T, Falchook G, Desai J, Kuo J, Strickler J, Krauss J, Li B, Denlinger C, Durm G, Ngang J, Henary H, Ngarmchamnanrith G, Rasmussen E, Morrow P, Hong D. OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC. Journal of Thoracic Oncology. Elsevier BV; 2019. p. S208–S208.